A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA

  • Authors:
    • P LISSONI
    • A ARDIZZOIA
    • S MEREGALLI
    • S BARNI
    • V FOSSATI
    • F BRIVIO
    • G TANCINI
  • View Affiliations

  • Published online on: November 1, 1994     https://doi.org/10.3892/or.1.6.1277
  • Pages: 1277-1280
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The advanced carcinoma of pancreas still remains an untreatable disease. Both chemotherapy and hormono-therapy seem not to prolong the survival time. Also immunotherapy with IL-2 has been shown to have no efficacy. Our experimental studies suggested the possibility of enhancing the antitumor activity of IL-2 by the administration of immunomodulating neurohormones, such as melatonin (MLT). This study was carried out to evaluate the efficacy of IL-2 plus MLT in advanced cancer of the pancreas. Fifty patients, with advanced adenocarcinoma of the pancreas, were randomized to receive chemotherapy consisting of 5-FU plus folates, endocrine therapy with LHRH and somatostatin analogues, supportive care alone or immunotherapy with subcutaneous low-dose IL-2 plus MLT. A partial response was obtained in 1/13 patients treated with chemotherapy and in 2/12 patients receiving immunotherapy; no tumor regression was seen in the other groups. The percent of survival at 1 year achieved in patients treated with immunotherapy was significantly higher than in the other groups tested (3/12 vs 1/38; p<0.02). This preliminary study would suggest that the immunotherapy with IL-2 plus MLT may represent a new promising treatment of advanced pancreatic adenocarcinoma.

Related Articles

Journal Cover

November 1994
Volume 1 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
LISSONI P, ARDIZZOIA A, MEREGALLI S, BARNI S, FOSSATI V, BRIVIO F and TANCINI G: A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA. Oncol Rep 1: 1277-1280, 1994
APA
LISSONI, P., ARDIZZOIA, A., MEREGALLI, S., BARNI, S., FOSSATI, V., BRIVIO, F., & TANCINI, G. (1994). A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA. Oncology Reports, 1, 1277-1280. https://doi.org/10.3892/or.1.6.1277
MLA
LISSONI, P., ARDIZZOIA, A., MEREGALLI, S., BARNI, S., FOSSATI, V., BRIVIO, F., TANCINI, G."A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA". Oncology Reports 1.6 (1994): 1277-1280.
Chicago
LISSONI, P., ARDIZZOIA, A., MEREGALLI, S., BARNI, S., FOSSATI, V., BRIVIO, F., TANCINI, G."A CLINICAL-STUDY OF IMMUNOTHERAPY VERSUS ENDOCRINE THERAPY VERSUS CHEMOTHERAPY IN THE TREATMENT OF ADVANCED PANCREATIC ADENOCARCINOMA". Oncology Reports 1, no. 6 (1994): 1277-1280. https://doi.org/10.3892/or.1.6.1277